With US Respiratory Pipeline Unlocked, Cipla Wants Lung Leadership

Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.

Lungs operation puzzle concept: hands of surgeon with surgical instruments (tools) perform lungs surgery as a result of respiratory disease, pneumonia, tuberculosis, bronchitis, asthma, lung abscess
Cipla Lays Out Respiratory Ambitions At JPM • Source: Shutterstock

Cipla Limited emphasized its global lung disease leadership aspirations at the J.P. Morgan Healthcare Conference, outlining an intent to double its footprint in the US, propelled by its respiratory and inhaler franchise and other segments such as peptide-based injectables, in addition to oral solids.

The Indian company, which “unlocked” its respiratory pipeline in the US with the launch of generic albuterol, has seen sales...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip